Literature DB >> 22752062

Neurological symptoms in individuals with fibrodysplasia ossificans progressiva.

Joseph A Kitterman1, Jonathan B Strober, Lixin Kan, David M Rocke, Amanda Cali, Jeannie Peeper, Jennifer Snow, Patricia L R Delai, Rolf Morhart, Robert J Pignolo, Eileen M Shore, Frederick S Kaplan.   

Abstract

Fibrodysplasia ossificans progressiva (FOP), a rare, disabling condition caused by gain-of-function mutations of a bone morphogenetic protein (BMP) type I receptor, leads to episodes of heterotopic ossification and resultant immobility. Neurological problems have not been associated with FOP, but neurological symptoms are commonly reported by FOP patients. To determine the prevalence of neurological symptoms and their characteristics in individuals with FOP, we conducted a survey of the 470 patient members of the International FOP Association (IFOPA) using a questionnaire about neurological symptoms. There were 168 responses (105 females, 63 males; age 1.5-68 years) from 30 countries representing 36 % of IFOPA members. Chronic neurological symptoms were reported by 86 (51 %). Prevalence of neuropathic pain (NP) was significantly increased (P < 0.001) compared to the general population, and tenfold more common in females (15 %) than males (1.6 %). Of those with NP, 94 % reported other sensory abnormalities. Prevalence of recurrent severe headaches (HA) (26 %) was similar to that in the general population, but prevalence in females with FOP (36 %) was almost fourfold greater than in males. Prevalence of NP, HA, and other sensory abnormalities was substantially higher in post-pubertal females; 33 % reported symptoms worsened during menstrual periods. Worsening of neurological symptoms during FOP flare-ups was reported by 23 %. Three patients with FOP (1.8 %) reported myoclonus, a prevalence much greater than reported in the general population (P < 0.001). Our worldwide survey indicates that neurological symptoms are common in FOP. We speculate that these symptoms are related to effects of dysregulated BMP signaling on the central and/or peripheral nervous systems.

Entities:  

Mesh:

Year:  2012        PMID: 22752062      PMCID: PMC3523705          DOI: 10.1007/s00415-012-6562-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  34 in total

1.  Influenza-like viral illnesses and flare-ups of fibrodysplasia ossificans progressiva.

Authors:  Richard F Scarlett; David M Rocke; Sharon Kantanie; Jean B Patel; Eileen M Shore; Frederick S Kaplan
Journal:  Clin Orthop Relat Res       Date:  2004-06       Impact factor: 4.176

2.  Substance P signaling mediates BMP-dependent heterotopic ossification.

Authors:  Lixin Kan; Vitali Y Lounev; Robert J Pignolo; Lishu Duan; Yijie Liu; Stuart R Stock; Tammy L McGuire; Bao Lu; Norma P Gerard; Eileen M Shore; Frederick S Kaplan; John A Kessler
Journal:  J Cell Biochem       Date:  2011-10       Impact factor: 4.429

3.  The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients.

Authors:  R B Cohen; G V Hahn; J A Tabas; J Peeper; C L Levitz; A Sando; N Sando; M Zasloff; F S Kaplan
Journal:  J Bone Joint Surg Am       Date:  1993-02       Impact factor: 5.284

Review 4.  Cyclooxygenase-2: a therapeutic target in angiogenesis.

Authors:  Miguel A Iñiguez; Antonio Rodríguez; Olga V Volpert; Manuel Fresno; Juan Miguel Redondo
Journal:  Trends Mol Med       Date:  2003-02       Impact factor: 11.951

Review 5.  Sex hormones and headache.

Authors:  S D Silberstein; G R Merriam
Journal:  J Pain Symptom Manage       Date:  1993-02       Impact factor: 3.612

6.  Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients.

Authors:  J M Connor; D A Evans
Journal:  J Bone Joint Surg Br       Date:  1982

Review 7.  Hormones and seizures.

Authors:  Nancy Foldvary-Schaefer; Cynthia Harden; Andrew Herzog; Tommaso Falcone
Journal:  Cleve Clin J Med       Date:  2004-02       Impact factor: 2.321

8.  Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype.

Authors:  Lixin Kan; Min Hu; William A Gomes; John A Kessler
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

9.  Epidemiology of headache in a general population--a prevalence study.

Authors:  B K Rasmussen; R Jensen; M Schroll; J Olesen
Journal:  J Clin Epidemiol       Date:  1991       Impact factor: 6.437

10.  Effects of indomethacin on demineralized bone-induced heterotopic ossification in the rat.

Authors:  P E DiCesare; M E Nimni; L Peng; M Yazdi; D T Cheung
Journal:  J Orthop Res       Date:  1991-11       Impact factor: 3.494

View more
  18 in total

1.  Cervical vertebral fusion with anterior meningocele.

Authors:  Mathew J Gallagher; Emmanuel Chavredakis; David Carter; Manesh Bhojak; Michael D Jenkinson; Simon R Clark
Journal:  Neuroradiol J       Date:  2015-04-13

2.  CNS demyelination in fibrodysplasia ossificans progressiva.

Authors:  Lixin Kan; Joseph A Kitterman; Daniele Procissi; Salin Chakkalakal; Chian-Yu Peng; Tammy L McGuire; Robert E Goldsby; Robert J Pignolo; Eileen M Shore; Frederick S Kaplan; John A Kessler
Journal:  J Neurol       Date:  2012-06-27       Impact factor: 4.849

3.  Myositis ossificans in children: a review.

Authors:  N K Sferopoulos; R Kotakidou; A S Petropoulos
Journal:  Eur J Orthop Surg Traumatol       Date:  2017-03-09

4.  Shared ACVR1 mutations in FOP and DIPG: Opportunities and challenges in extending biological and clinical implications across rare diseases.

Authors:  Harry J Han; Payal Jain; Adam C Resnick
Journal:  Bone       Date:  2017-08-02       Impact factor: 4.398

5.  Opioid signaling in mast cells regulates injury responses associated with heterotopic ossification.

Authors:  Lixin Kan; Amelia A Mutso; Tammy L McGuire; Apkar Vania Apkarian; John A Kessler
Journal:  Inflamm Res       Date:  2013-12-11       Impact factor: 4.575

6.  Drosophila Nociceptive Sensitization Requires BMP Signaling via the Canonical SMAD Pathway.

Authors:  Taylor L Follansbee; Kayla J Gjelsvik; Courtney L Brann; Aidan L McParland; Colin A Longhurst; Michael J Galko; Geoffrey K Ganter
Journal:  J Neurosci       Date:  2017-08-03       Impact factor: 6.167

Review 7.  Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders.

Authors:  Maurizio Pacifici; Eileen M Shore
Journal:  Cytokine Growth Factor Rev       Date:  2015-12-28       Impact factor: 7.638

Review 8.  Left to themselves: Time to target chronic pain in childhood rare diseases.

Authors:  Christine B Sieberg; Alyssa Lebel; Erin Silliman; Scott Holmes; David Borsook; Igor Elman
Journal:  Neurosci Biobehav Rev       Date:  2021-03-24       Impact factor: 8.989

Review 9.  ACVR1 mutations in DIPG: lessons learned from FOP.

Authors:  Kathryn R Taylor; Maria Vinci; Alex N Bullock; Chris Jones
Journal:  Cancer Res       Date:  2014-08-18       Impact factor: 12.701

Review 10.  Cardiopulmonary and Neurologic Dysfunctions in Fibrodysplasia Ossificans Progressiva.

Authors:  Fatima Khan; Xiaobing Yu; Edward C Hsiao
Journal:  Biomedicines       Date:  2021-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.